Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease
Robert A. Rissman(University of Southern California), Oliver Langford(University of Southern California), Jennifer Ngolab(University of Southern California), Kristopher M. Kirmess(C2N Diagnostics (United States)), Michael S. Rafii(University of Southern California), Charisse N. Winston(University of Southern California), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Tim West(C2N Diagnostics (United States)), Paul Aisen(University of California, San Diego), Sara Abdel‐Latif(University of Southern California), Matthew R. Meyer(C2N Diagnostics (United States)), Joel B. Braunstein(C2N Diagnostics (United States)), Gustavo Jimenez‐Maggiora(University of Southern California), Kevin E. Yarasheski(Washington University in St. Louis), Traci L. Wente‐Roth(C2N Diagnostics (United States)), Rema Raman(University of Southern California), Keith A. Johnson(Brigham and Women's Hospital), Reisa A. Sperling(Harvard University), Michael C. Irizarry(Eisai (United States))
Cited by 147
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k